OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
PAR:OSE
Price:
6.06
EUR
-0.41%
Market Closed
Market Cap:
135.4m
EUR
Balance Sheet
Balance Sheet Decomposition
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA
| Current Assets | 69.9m |
| Cash & Short-Term Investments | 16.7m |
| Receivables | 4.1m |
| Other Current Assets | 49m |
| Non-Current Assets | 54m |
| Long-Term Investments | 6.4m |
| PP&E | 3.4m |
| Intangibles | 44m |
| Other Non-Current Assets | 192k |
Balance Sheet
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA
Currency: EUR
Millions
Annual
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
9
|
15
|
10
|
10
|
26
|
29
|
34
|
26
|
19
|
0
|
|
| Cash |
1
|
0
|
2
|
4
|
0
|
0
|
22
|
19
|
6
|
0
|
|
| Cash Equivalents |
9
|
15
|
7
|
5
|
26
|
29
|
11
|
7
|
13
|
0
|
|
| Short-Term Investments |
6
|
3
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
2
|
16
|
9
|
10
|
5
|
8
|
8
|
8
|
9
|
4
|
|
| Accounts Receivables |
0
|
12
|
0
|
2
|
1
|
1
|
1
|
0
|
1
|
0
|
|
| Other Receivables |
2
|
4
|
9
|
7
|
5
|
7
|
7
|
8
|
8
|
0
|
|
| Other Current Assets |
0
|
3
|
2
|
1
|
2
|
2
|
3
|
3
|
3
|
49
|
|
| Total Current Assets |
17
|
37
|
24
|
23
|
33
|
40
|
44
|
37
|
30
|
70
|
|
| PP&E Net |
0
|
0
|
0
|
1
|
3
|
4
|
5
|
5
|
4
|
3
|
|
| PP&E Gross |
0
|
0
|
0
|
1
|
3
|
4
|
5
|
5
|
4
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
1
|
2
|
3
|
4
|
0
|
|
| Intangible Assets |
0
|
53
|
53
|
53
|
53
|
53
|
51
|
49
|
46
|
44
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
6
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
17
N/A
|
90
+427%
|
77
-14%
|
77
-1%
|
89
+16%
|
97
+9%
|
102
+5%
|
92
-10%
|
82
-11%
|
124
+51%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
4
|
9
|
7
|
7
|
10
|
10
|
9
|
9
|
8
|
|
| Accrued Liabilities |
0
|
3
|
1
|
1
|
2
|
2
|
4
|
3
|
2
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
1
|
1
|
1
|
1
|
2
|
4
|
7
|
8
|
|
| Other Current Liabilities |
1
|
11
|
4
|
1
|
5
|
1
|
1
|
1
|
0
|
2
|
|
| Total Current Liabilities |
2
|
19
|
14
|
9
|
14
|
14
|
17
|
16
|
19
|
20
|
|
| Long-Term Debt |
0
|
1
|
4
|
4
|
11
|
19
|
35
|
41
|
39
|
38
|
|
| Deferred Income Tax |
0
|
5
|
3
|
2
|
5
|
2
|
2
|
2
|
1
|
1
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
|
| Total Liabilities |
3
N/A
|
25
+893%
|
22
-12%
|
15
-31%
|
30
+101%
|
36
+17%
|
54
+52%
|
59
+10%
|
59
0%
|
60
+2%
|
|
| Equity | |||||||||||
| Common Stock |
2
|
3
|
3
|
3
|
3
|
4
|
4
|
4
|
4
|
4
|
|
| Retained Earnings |
8
|
13
|
4
|
10
|
7
|
8
|
21
|
36
|
58
|
18
|
|
| Additional Paid In Capital |
21
|
49
|
49
|
49
|
48
|
65
|
66
|
66
|
77
|
78
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
14
N/A
|
65
+346%
|
55
-14%
|
62
+11%
|
59
-5%
|
61
+5%
|
48
-22%
|
33
-32%
|
23
-30%
|
64
+178%
|
|
| Total Liabilities & Equity |
17
N/A
|
90
+427%
|
77
-14%
|
77
-1%
|
89
+16%
|
97
+9%
|
102
+5%
|
92
-10%
|
82
-11%
|
124
+51%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
10
|
14
|
14
|
15
|
15
|
18
|
18
|
18
|
22
|
22
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
